Over the past year or so, investors have come back to the med-tech space
and pushed valuations back up to levels closer to historical norms.
Although that means a lot of easy money is gone, many of these companies
still hold worthwhile potential as long-term holdings. Among them,
Stryker (SYK)
may still be among the most interesting. Not only does this
well-regarded med-tech stock have an improving ortho market to exploit,
but the company is something of a free agent in terms of using M&A
to further expand its long-term revenue possibilities.
Continue to Seeking Alpha here:
Stryker Seems Back On Track, But There's Work To Do
No comments:
Post a Comment